Aeolus Pharmaceuticals (PK) Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aeolus Pharmaceuticals Inc (PK) AOLS OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.0061 16:00:00
Open Price Low Price High Price Close Price Prev Close
0.0061 0.0061 0.0061 0.0061 0.0061
Bid Price Ask Price Spread News
0.0061 0.007 0.0009 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1 15,000 $ 0.0061 $ 92 - 0.001 - 0.02
Last Trade Time Type Quantity Stock Price Currency
09:30:04 15,000 $ 0.0061 USD

Aeolus Pharmaceuticals (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 927.72k 152.09M 53.78M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
8.04k $ - 0.00% - -

more financials information »

Aeolus Pharmaceuticals (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AOLS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.007050.0080.0050.0067198195,944-0.00095-13.48%
1 Month0.0080.01160.0020.0060082353,877-0.0019-23.75%
3 Months0.00410.020.0020.0079438585,7030.00248.78%
6 Months0.00190.020.00110.006069511,2050.0042221.05%
1 Year0.0010.020.0010.005633321,0060.0051510.0%
3 Years0.0040.020.000450.0039309220,0970.002152.5%
5 Years0.180.500.000450.0197333144,340-0.1739-96.61%

Aeolus Pharmaceuticals (PK) Description

Aeolus is developing a portfolio of novel metalloporphyrins, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed, with funding from the US Department of Health and Human Services, as a MCM against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to develop the compound for the treatment of lung fibrosis, including IPF and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy. The Company is also developing AEOL 11114 as a treatment for Parkinson's disease and AEOL 20415 as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti-viral therapies. For more information, please visit Aeolus's corporate website at

Your Recent History
Aeolus Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.